The therapy, dubbed OST-HER2, uses a HER2-bioengineered form of the bacteria Listeria monocytogenes to trigger an immune ...

A month after halting dosing in two of the three treatment arms of a phase 2 trial of its pulmonary arterial hypertension ...

The FDA is elevating a recall from Philips related to one of its wearable outpatient heart monitors, used to help detect ...

GE HealthCare is launching a new imaging research collaboration with the University of California, San Francisco, aimed at ...

Neumora Therapeutics’ phase 3 fail was worse than analysts feared. | Neumora Therapeutics’ phase 3 fail was worse than ...

And while Wood said the pharma still isn’t interested in joining the overcrowded obesity landscape, GSK is considering ways ...

Take a look back at the biggest stories of the week with Fierce Biotech’s conference's kickoff coverage here | Welcome to day ...

While deep-brain stimulation therapy has been available for people with Parkinson’s disease for decades, Medtronic has now ...

Sling Therapeutics’ oral challenger to Amgen’s intravenous Tepezza has hit the mark in a phase 2b/3 thyroid eye disease (TED) ...

Even before that deal, AbbVie had been showing an interest in the modality, with then-CEO Richard Gonzalez telling analysts ...

Welcome to Day 2 of the J.P. Morgan Healthcare Conference 2025 in San Francisco. | Welcome to Day 2 of the J.P. Morgan ...

After spending the past year extending its portfolio of continuous glucose monitors to include people who may not have ...